William Lewis Sells 18,750 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of Insmed stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $77.79, for a total transaction of $1,458,562.50. Following the completion of the transaction, the chief executive officer now directly owns 334,186 shares of the company’s stock, valued at $25,996,328.94. This trade represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

William Lewis also recently made the following trade(s):

• On Tuesday, February 18th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $81.03, for a total transaction of $1,519,312.50.
• On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The shares were sold at an average price of $80.90, for a total value of $6,419,415.00.
• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.94, for a total value of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The shares were sold at an average price of $70.18, for a total transaction of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The stock was sold at an average price of $63.36, for a total transaction of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The shares were sold at an average price of $66.02, for a total transaction of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50.

Insmed Stock Up 0.4 %

Shares of INSM stock opened at $77.55 on Thursday. The company’s fifty day simple moving average is $75.46 and its two-hundred day simple moving average is $73.84. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The stock has a market cap of $14.04 billion, a P/E ratio of -13.87 and a beta of 1.11. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The firm had revenue of $104.44 million during the quarter, compared to analysts’ expectations of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Analysts predict that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on INSM shares. Guggenheim restated a “buy” rating and set a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. Truist Financial boosted their target price on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Morgan Stanley increased their price target on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Wells Fargo & Company boosted their price objective on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Finally, Stifel Nicolaus reduced their price target on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, Insmed presently has an average rating of “Moderate Buy” and an average price target of $91.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of INSM. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Insmed in the fourth quarter worth $6,798,000. Mackenzie Financial Corp lifted its position in Insmed by 12.5% during the fourth quarter. Mackenzie Financial Corp now owns 10,883 shares of the biopharmaceutical company’s stock valued at $751,000 after purchasing an additional 1,213 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Insmed in the 4th quarter worth $259,000. Fourth Dimension Wealth LLC bought a new stake in shares of Insmed in the 4th quarter worth about $278,000. Finally, Vise Technologies Inc. raised its position in shares of Insmed by 6.3% during the 4th quarter. Vise Technologies Inc. now owns 5,634 shares of the biopharmaceutical company’s stock valued at $389,000 after buying an additional 336 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.